Future. Ready.

2021-2022 Annual Report

Message From the Board Chair

On behalf of the Board of Directors, I’m pleased to present CADTH’s 2021–2022 Annual Report, chronicling a pivotal year in the ongoing evolution of CADTH.

As the COVID-19 pandemic stretched into its second year, the great team at CADTH once again demonstrated its resilience in the face of health system upheaval, meeting the demand for credible evidence on topics ranging from virtual care to mental health to SARS-CoV-2.

New and expanded collaborations with Choosing Wisely Canada, the Canadian Institutes of Health Research, and other Canadian and international organizations provided recommendations to reduce low-value care post-pandemic, informed the optimal use of real-world evidence, and supported CADTH’s first therapeutic review in oncology.

A request from Health Canada to convene an advisory panel to develop a framework for a potential pan-Canadian formulary was a clear vote of confidence in CADTH.

While these accomplishments and many others noted in this report enhance CADTH’s value as a trusted health system resource in Canada, what made this a pivotal — even transformative — year was the launch of an ambitious new strategic plan for 2022–2025.

Anchored in CADTH’s strengths and expertise — and informed by a clear understanding of the shifting health care environment based on extensive consultations across all health sectors — Ahead of the Curve: Shaping Future-Ready Health Systems positions CADTH to maximize its contributions to and impact on health care in Canada.

My congratulations to President and CEO Suzanne McGurn and CADTH’s management team and staff for meeting the health system needs of today while preparing to meet the changing demands the coming years will bring.

David Agnew

David Agnew

Board Chair

Message From the President and CEO

My second year as President and CEO of CADTH was shaped in large part by the global response to the COVID-19 pandemic, which continued to impact the needs of senior health decision-makers and the environment for health technology assessment (HTA). Since the start of the pandemic, HTA agencies in Canada and beyond have learned in real time how to provide relevant, timely, and useful information and guidance in an imperfect world with imperfect evidence.

COVID-19 was also a factor in our decision to extend the 2019–2021 CADTH Strategic Plan for an additional year. This gave us the opportunity to engage a substantially wider range of stakeholders, evidence users, and evidence producers in the development of our new 2022–2025 Strategic Plan.

Our learnings from COVID-19 and our robust new strategic plan better position CADTH to help health systems fully harness the value health of technologies and improve patient care and population outcomes.

I’d like to personally thank CADTH’s leadership team, staff, experts, and consultants who contributed to our work, often under trying circumstances, and the individuals and organizations who contributed their ideas, priorities, and thoughts to our new strategic plan.

Finally, my thanks to David Agnew and the members of CADTH’s Board of Directors for their exceptional support and guidance.

I remain committed to building and strengthening relationships within every health care sector and look forward to working with colleagues, senior health decision-makers, and stakeholders — old and new — as we implement our new strategic plan over the next 3 years.

Suzanne McGurn

Suzanne McGurn

President and CEO



When Canada’s health care decision-makers want to know what the evidence says, they ask CADTH, Canada’s drug and health technology agency.

CADTH was established by Canada’s federal, provincial, and territorial governments to be a trusted source of independent information and advice for the country’s publicly funded health care systems.

Health administrators and policy experts rely on CADTH to help inform their decisions about the life cycle management of drugs, devices, and services used to prevent, diagnose, and treat medical conditions.

CADTH recognizes the inherent and treaty rights of all First Nations, Inuit, and Métis peoples across this land. We acknowledge the harms and mistakes of the past and are committed to moving forward in partnership with Indigenous communities in a spirit of reconciliation and collaboration.


CADTH staff live and work across the country on lands that are the traditional home to many past, present, and future First Nations, Inuit, and Métis Peoples. We acknowledge the deep significance of these territories and are grateful to have the opportunity to work on these lands.


Hospital image
Enabling Future-Ready Health Care

Enabling Future-Ready Health Care systems across Canada and around the world are experiencing immense pressure.


The pan-Canadian public-policy environment has never been more complex, shaped by:

  • more demographic diversity
  • more disruptive science and technological innovation
  • more empowered patients who take ownership of their own care
  • more awareness of the urgent need to address profound social and health inequities
  • more demands on finite resources

On top of this, COVID-19 has changed our health systems forever. The crisis demanded an unprecedented response from health leaders across the country, at every level of government and in every community — including CADTH.

Working with partners from the public sector and beyond, CADTH approached its work in new ways that responded to the urgency of the pandemic. We rose to the challenge, leading to more collaborations, closer connections with decision-makers and clinicians, and ultimately, more responsible and agile evaluation and adoption of new diagnostics, drugs, and other health technologies.

These new ways of working and collaborating represent CADTH’s standard moving forward.



why cadth

CADTH Products and Services

CADTH’s work is used by senior health policy decision-makers to inform important decisions about the appropriate use of drugs, medical devices, and clinical interventions.


Our primary programs and services include:

Horizon Scans A high-level summary of a new or emerging health technology that is likely to have a significant impact on the delivery of health care in Canada.
Reference Lists A compilation of references on a specific health care topic, with abstracts and links to full-text documents, if available.
Reimbursement Reviews A comprehensive assessment of a drug or drug class that includes clinical effectiveness, pharmacoeconomic analysis, and clinician and patient perspectives. These assessments inform non-binding recommendations that help guide Canada’s federal, provincial (exception Quebec), and territorial governments’ reimbursement decisions. Implementation advice and funding algorithms are provided if applicable.
Health Technology Reviews

A customized review of a health technology that may consist of one — or a combination — of the following:

  • An environmental scan
  • A rapid review
  • A clinical review
  • A pharmacoeconomic review
  • Patient perspectives
  • Any legal, ethical, social, implementation, environmental, and policy implications.

Appropriate use recommendations are provided if applicable.


Other products and services

Scientific Advice Advice to pharmaceutical companies on their early drug development plans from a health technology assessment perspective.
Support & Knowledge Mobilization
Specialized products, tools, and services to help health care decision-makers use and implement CADTH information, recommendations, and advice.
Canadian Journal
of Health Technologies

An open-access journal serving the Canadian and global health technology assessment community.

Looking Ahead


Our experience over the past several years has shown that CADTH has the resilience to thrive in the face of uncertainty and the potential to grow along with the evolving drug and device decision-making landscape.

With the CADTH 2022–2025 Strategic Plan as our guide, CADTH will centre its work around impact — maximizing our efforts to directly inform the decisions and actions undertaken by policy-makers, in the work of research and clinicians, and in the lives of patients.

We will also be working with Health Canada in the upcoming fiscal year on a new 5-year contribution agreement, to ensure we have the resource needed to contribute to the Government of Canada’s efforts to maintain and improve the health of all people in Canada.

As new ideas, new thinking, and new challenges emerge on the health care horizon, CADTH will provide decision-makers with the right evidence at the right time. We’re reshaping how evidence can be used to drive access, quality, value, and sustainability. CADTH will be an incubator of evidence-informed, innovative solutions to help system challenges and a catalyst for future-ready transformations.

CADTH is ready to step boldly out in front, to bring foresight and focus to health leaders, health systems, and the patients and populations they service across Canada, using evidence as a tool for channeling hope into action.


A Special Thank You to Our Valued Stakeholder Community


Thank you to everyone who contributed to CADTH’s work in FY 2021–2022.

We sincerely appreciate the counsel from our advisory committees, knowledge shared by our expert committees, and input and feedback we receive from industry, clinicians, and patient groups.


Financial Statements